Amycretins unique position: Its the only molecule in late-stage development that offers both a competitive subcutaneous formulation AND a potentially game-changing oral formulation
GLP-1 plays a key role in central satiety signaling and is known to delay gastric emptying, enhance satiety, and promote weight reduction in patients with DM [11]
Zepbound (tirzepatide): Manufactured by Eli Lilly and FDA-approved for chronic weight management, Zepbound contains the same active ingredient as Mounjaro and has been referenced in current GLP-1 litigation
For instance, weight loss alone can decrease the risk of cardiovascular disease, improve sleep apnea, alleviate joint pain and more
For patients currently in compounded GLP-1 programs, the transition would likely involve one of several options: switching to an FDA-approved branded medication (at substantially higher cost), discussing alternative weight management approaches with a licensed provider, or exploring whether 503A patient-specific compounding applies to their individual clinical situation
